261 ABO-Incompatible Heart Transplantation in Infants: Analysis of the Pediatric Heart Transplant Study (PHTS) Database

2011 ◽  
Vol 30 (4) ◽  
pp. S92 ◽  
Author(s):  
H.T. Henderson ◽  
C.E. Canter ◽  
W.T. Mahle ◽  
A.I. Dipchand ◽  
K. LaPorte ◽  
...  
2019 ◽  
Vol 23 (5) ◽  
Author(s):  
Joshua D. Sparks ◽  
Ryan S. Cantor ◽  
Elizabeth Pruitt ◽  
James K. Kirklin ◽  
Michael Carboni ◽  
...  

2014 ◽  
Vol 19 (1) ◽  
pp. 16-24 ◽  
Author(s):  
Gilbert J. Burckart ◽  
William D. Figg ◽  
Maria M. Brooks ◽  
Dionna J. Green ◽  
Sarah M. Troutman ◽  
...  

OBJECTIVES Earlier studies have indicated that the pharmacokinetics of mycophenolic acid (MPA) is influenced by polymorphisms of ABCC2, which encodes for the membrane transporter MRP2. The ABCC2 rs717620 A allele has been associated with enterohepatic recirculation of MPA, and our previous work had correlated the discontinuance of MPA with this allele in pediatric heart transplant patients. Therefore, we hypothesized that the ABCC2 rs717620 A allele would be associated with poorer outcomes including rejection with hemodynamic compromise (RHC), graft failure, and death in the pediatric heart transplant (PHTx) population receiving MPA. METHODS PHTx recipients from 6 institutions in the Pediatric Heart Transplantation Study (PHTS) from the period of 1993–2009, receiving MPA therapy, were genotyped for ABCC2 rs717620. Genotyping was accomplished by direct sequencing. Demographic and outcome data were limited to the data routinely collected as part of the PHTS and included RHC and mortality. RESULTS Two hundred ninety patients were identified who received MPA at some point post transplantation, of which 200 carried the GG genotype, 81 carried the AG genotype, and 9 carried the AA genotype. Follow-up time after transplantation was 6 years. RHC occurred in 76 patients and 18 patients died. In the 281 patients followed up more than 1 year, late RHC (>1 year post transplantation) occurred in 42 patients. While both RHC and late RHC were associated with the ABCC2 rs717620 GG genotype (hazard ratios: 1.80 and 4.57, respectively, p<0.05) in all patients, this association was not significant in PHTx patients receiving only MPA as the antiproliferative agent from the time of transplant (n=142). CONCLUSIONS ABCC2 rs717620 polymorphisms varied within racial groups. As a candidate gene assessment, the ABCC2 rs717620 AG and AA genotypes may be associated with improved, rather than poorer, RHC in PHTx patients receiving MPA therapy. ABCC2 rs717620 polymorphisms should be included in any expanded pharmacogenomic analysis of outcomes after pediatric heart transplantation.


2011 ◽  
Vol 30 (12) ◽  
pp. 1395-1402 ◽  
Author(s):  
Kevin P. Daly ◽  
Sujata B. Chakravarti ◽  
Margaret Tresler ◽  
David C. Naftel ◽  
Elizabeth D. Blume ◽  
...  

2015 ◽  
Vol 25 (S2) ◽  
pp. 131-139 ◽  
Author(s):  
Yuk M. Law

AbstractPaediatric heart transplantation has evolved over the last 3 decades. The research group, Pediatric Heart Transplant Study, has been in step with that evolution over the nearly 20 years of its existence by utilising its registry to contribute a wealth of clinical research to the field. The highlights of its studies will be presented in this review.


2018 ◽  
Vol 28 (2) ◽  
pp. 170-173
Author(s):  
Meghann McKane ◽  
Debra A. Dodd ◽  
Bret A. Mettler ◽  
Kari A. Wujcik ◽  
Justin Godown

Background: Many pediatric heart transplant recipients live a significant distance from their transplant center. This results in families either traveling long distances or relying on outside physicians to assume aspects of their care. Distance has been implicated to play a role in congenital heart disease outcomes, but its impact on heart transplantation has not been reported. The aim of this study was to assess the impact of distance on pediatric heart transplant outcomes. Methods: The Scientific Registry of Transplant Recipients database was queried for all pediatric heart transplant recipients from large US children’s hospitals (1987-2014). Patients were stratified into 4 groups (<20, 20-50, 50-100, and >100 miles) based on distance. Survival curves were generated and compared using the log-rank test. Cox proportional hazards regression was performed to adjust for differences between groups. Results: A total of 4768 patients were included in the analysis, of which 1435 (30.1%) were <20 miles, 940 (19.7%) were 20 to 50 miles, 806 (16.9%) were 50 to 100 miles, and 1587 (33.3%) were >100 miles from their transplant center. There was no difference in posttransplant survival based on distance after adjusting for patient age, gender, ethnicity, blood type, diagnosis, listing status, and the need for pretransplant ventricular assist device, extracorporeal membrane oxygenation, or ventilator support. Conclusion: There is no significant difference in graft survival after pediatric heart transplantation based on patient distance from their transplant center. Our data suggest the current strategy of transitioning some aspects of transplant care to local physicians or management from a distance does not increase posttransplant mortality risk.


Sign in / Sign up

Export Citation Format

Share Document